证券代码：601066 证券简称：中信建投 公告编号：临 2025-056 号 中信建投证券股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 问题征集：股东及其他投资者可于 2025 年 10 月 28 日（星期二）至 11 月 3 日 （星期一）16:00 前，登录上证路演中心网站首页，点击"提问预征集"栏目或 通过公司邮箱（601066@csc.com.cn）进行提问。在信息披露允许的范围内，公 司将在说明会上对投资者普遍关注的问题进行回答。 中信建投证券股份有限公司（以下简称公司）将于 2025 年 10 月 30 日（星 期四）披露公司 2025 年第三季度报告，为便于广大投资者更加全面深入地了解 公司 2025 年前三季度经营情况，公司将于 2025 年 11 月 4 日（星期二）16:00-17:00 召开 2025 年第三季度业绩说明会，就投资者普遍关注的问题进行交流。 一、说明会类型 二、说明会召开的时间、地点 （一）召开时间：20 ...

专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2025可持续全球领导者大会于10月16日-18日在上海市黄浦区世博园区召开。中国银河证券董事长王 晟，中信建投证券董事长、执委会主任刘成，中信证券总经理邹迎光，招商证券总裁朱江涛，光大证券 总裁刘秋明，国联民生证券总裁葛小波等中国顶级券商"掌舵人"齐聚#可持续全球领导者大会#，共议如 何以金融"五篇大文章"构筑证券可持续发展新生态！ 全文|银河证券董事长王晟：以金融"五篇大文章"实践，贡献可持续发展中国智慧 全文丨中信建投证券董事长、执委会主任刘成：证券机构如何做实做好"五篇大文章" 全文|中信证券邹迎光：扎实做好金融"五篇大文章"，助力中国经济高质量发展，构筑证券业新生态 全文丨招商证券总裁朱江涛详解"深耕'五篇大文章'的创新实践" 全文|光大证券总裁刘秋明：将ESG融入发展全流程，锚定一流服务型投行 全文丨国联民生证券总裁葛小波：呼吁以全球化视野推动多元化交易发展 2025可持续全球领导者大会由世界绿色设计组织（WGDO）与新浪集团联合主办，国际财务报告准则 基金 ...

Core Points - The stock of Huayu Pharmaceutical (688553.SH) closed at 21.28 yuan, reflecting a decline of 2.96% and is currently in a state of breaking below its initial public offering price [1] - Huayu Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1] - On the first day of trading, the stock reached a peak of 42.59 yuan, marking the highest price since its listing [1] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, which was 453 million yuan more than the original plan [1] - The company intended to raise 1.907 billion yuan for projects including the construction of a second phase of the EU-standard injection production base and the establishment of an innovative drug research institute, as well as to supplement working capital [1] - The total issuance costs were 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities amounting to 98.875 million yuan [1]

上市当日，汇宇制药盘中最高报42.59元，创上市以来股价最高点。 中国经济网北京10月23日讯汇宇制药(688553.SH)今日收报21.28元，跌幅2.96%。目前该股处于破发状 态。 2021年10月26日，汇宇制药在上交所科创板上市，公开发行股票6360.00万股，发行价格为38.87元/股， 保荐机构、主承销商为中信建投（601066）证券，保荐代表人为杨泉、田斌，联席主承销商为国都证 券。 汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制药最终 募集资金净额比原计划多4.53亿元。汇宇制药于2021年10月18日披露的招股书显示，公司拟募集资金 19.07亿元，分别用于汇宇欧盟标准注射剂产业化基地(二期)项目、汇宇创新药物研究院建设项目、补充 流动资金。 ...

Core Points - Weijie Chuangxin (688153.SH) closed at 34.06 yuan, with a decline of 3.32%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 12, 2022, with an initial public offering (IPO) of 40.08 million shares at a price of 66.60 yuan per share [1] - The total amount raised from the IPO was 2.669 billion yuan, with a net amount of 2.502 billion yuan after deducting issuance costs, exceeding the original plan by 15.29 million yuan [1] - The funds raised are intended for integrated circuit production testing projects, research and development center construction projects, and to supplement working capital [1] - The total issuance costs for the IPO amounted to 166.82 million yuan, with underwriting and sponsorship fees accounting for 147.31 million yuan [1]

Core Points - The stock price of DiAo Micro (688381.SH) has decreased by 4.44%, closing at 25.84 yuan [1] - DiAo Micro was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 23, 2022, with an initial public offering (IPO) of 63.05 million shares at a price of 41.68 yuan per share [1][2] - The stock reached its highest price of 55.50 yuan on its first trading day but is currently in a state of decline [2] Fundraising and Financials - DiAo Micro raised a total of 262.79 million yuan from its IPO, with a net amount of 241.56 million yuan after deducting issuance costs, exceeding the original plan by 91.56 million yuan [2] - The company initially aimed to raise 150 million yuan for projects including the upgrade and industrialization of simulation chip products, the construction of a research and design center in Shanghai, a research and testing center in Nantong, and to supplement working capital [2] - The total issuance costs for the IPO amounted to 21.23 million yuan, with underwriting and sponsorship fees accounting for 18.08 million yuan [3]

Group 1 - The core point of the news is that Tongniu Information has seen a stock price increase of 5.23%, reaching 44.67 CNY per share, with a total market capitalization of 6.29 billion CNY [1] - Tongniu Information, established on September 21, 2005, and listed on September 24, 2020, is a comprehensive internet service provider based in Beijing, specializing in internet data center services, cloud services, internet access services, and application software development [1] - The revenue composition of Tongniu Information includes 66.76% from IDC and value-added services, 21.48% from other internet services, 10.00% from IDC and cloud platform system integration, and 1.76% from other supplementary services [1] Group 2 - Citic Securities Investment Fund has a significant holding in Tongniu Information, with the Citic Securities Zhenxuan Growth Mixed Fund A (018788) holding 17,000 shares, accounting for 3.44% of the fund's net value, making it the fourth-largest holding [2] - The Citic Securities Zhenxuan Growth Mixed Fund A was established on August 8, 2023, with a latest scale of 14.68 million CNY, achieving a year-to-date return of 20.24% [2] - The fund manager, Zhang Qing, has been in position for 4 years and 182 days, with the fund's total asset size at 22.83 million CNY, and the best and worst returns during his tenure being 21.35% and -20.83%, respectively [3]

Core Viewpoint - CITIC Securities maintains a "Buy" rating for Innovent Biologics (01801), projecting revenues of 11.806 billion yuan, 15.382 billion yuan, and 21.092 billion yuan for 2025-2027, respectively, with a DCF valuation indicating a fair market value of 221.5 billion HKD and a target price of 129.61 HKD [1] Group 1 - The company has established a significant presence in the oncology sector, with high-value clinical products expected to enhance revenue and reduce marginal costs [1] - In non-oncology sectors, the company has made extensive investments in metabolism, autoimmune diseases, and ophthalmology, with competitive and advanced products both launched and in development [1] Group 2 - On October 22, Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical, which will pay 1.2 billion USD upfront, including a strategic equity investment of 100 million USD at a subscription price of 112.56 HKD per share, representing a 20% premium over the weighted average share price of the past 30 trading days [1] - The total value of the collaboration could reach 11.4 billion USD, with Innovent Biologics and Takeda jointly developing IBI363 (PD-1/IL-2α-bias) [1] - Innovent Biologics granted Takeda exclusive rights for IBI343 (CLDN18.2ADC) outside Greater China and exclusive options for IBI3001 (EGFR/B7H3ADC) outside Greater China [1]

Core Insights - Dongyue Silicon Material (300821.SZ) reported a significant decline in revenue and net profit for the first three quarters of 2025, with revenue at 3.03 billion yuan, down 24.76% year-on-year, and net profit attributable to shareholders at 2.86 million yuan, down 96.78% [1][2] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 3.03 billion yuan, a decrease of 24.76% compared to the previous year [1][2] - The net profit attributable to shareholders was 2.86 million yuan, reflecting a 96.78% decline year-on-year [1][2] - The net profit excluding non-recurring gains and losses was 11.82 million yuan, down 87.60% year-on-year [1][2] - The net cash flow from operating activities was 264 million yuan, an increase of 35.94% year-on-year [1][2] Year-on-Year Comparison - In 2024, the company reported operating revenue of 5.15 billion yuan, a year-on-year increase of 7.27% [3] - The net profit attributable to shareholders for 2024 was 56.76 million yuan, compared to a loss of 271.12 million yuan in the previous year, marking a 120.94% improvement [3] - The net profit excluding non-recurring gains and losses for 2024 was 74.36 million yuan, up 127.29% from a loss of 272.51 million yuan in 2023 [3] - The net cash flow from operating activities in 2024 was 216 million yuan, a significant increase of 260.73% compared to the previous year [3] Fundraising and Use of Proceeds - Dongyue Silicon Material raised a total of 2.07 billion yuan through its IPO, with a net amount of 1.99 billion yuan after deducting issuance costs [4] - The company initially planned to raise 4.5 billion yuan, with 2.98 billion yuan allocated for a 300,000 tons/year organic silicon monomer and 200,000 tons/year downstream product processing project [4] - Additional allocations included 498 million yuan for energy-saving and environmental protection upgrades, 200 million yuan for an organic silicon R&D center, and 821 million yuan for working capital [4]

Core Viewpoint - CITIC Securities maintains a "Buy" rating for Innovent Biologics (01801), projecting revenues of 11.806 billion, 15.382 billion, and 21.092 billion CNY for 2025-2027, with a DCF valuation suggesting a fair market value of 221.5 billion HKD and a target price of 129.61 HKD [1] Group 1: Financial Projections - Expected revenues for Innovent Biologics from 2025 to 2027 are 11.806 billion CNY, 15.382 billion CNY, and 21.092 billion CNY respectively [1] - The company's fair market value is estimated at 221.5 billion HKD based on DCF valuation [1] - Target price set at 129.61 HKD [1] Group 2: Strategic Developments - On October 22, Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical, which includes a 1.2 billion USD upfront payment [1] - The upfront payment consists of a 100 million USD strategic equity investment at a subscription price of 112.56 HKD per share, representing a 20% premium over the weighted average share price of the last 30 trading days [1] - The total value of the collaboration deal is up to 11.4 billion USD [1] Group 3: Product Pipeline and Market Position - Innovent Biologics has established a significant presence in the oncology sector, with high-value clinical products expected to enhance revenue and reduce marginal costs [1] - In non-oncology areas, the company has made extensive advancements in metabolism, autoimmune diseases, and ophthalmology, with competitive and advanced products both in the market and under development [1] - Innovent Biologics grants Takeda exclusive rights for IBI343 (CLDN18.2 ADC) outside Greater China and exclusive options for IBI3001 (EGFR/B7H3 ADC) outside Greater China [1]